Prognostic radiology: Quantitative assessment of tumor oxygen dynamics by MRI

Dawen Zhao, Anca Constantinescu, Lan Jiang, Eric W. Hahn, Ralph P. Mason

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

It is generally recognized that tumor hypoxia has a strong influence over therapeutic outcome in the clinic. The authors have developed an oximetry approach using 19F echo planar magnetic resonance imaging-FREDOM (Fluorocarbon Relaxometry using Echoplanar imaging for Dynamic Oxygen Mapping), which reveals dynamic changes based on sequential maps of regional tumor PO2. Preclinical investigations focused on diverse sublines of the Dunning prostate R3327 tumor. As expected, intratumoral heterogeneity was considerable. However, large tumors (>3.5 cm3) were significantly less well oxygenated than smaller tumors (<2 cm3). Faster growing, less differentiated tumors were less well oxygenated than size-matched tumors of slower growing sublines. The greatest potential of this technique is the ability to follow the fate of individual tumor regions with respect to interventions. For each subline, there was a significant response to respiratory challenge with oxygen for initially well-oxygenated regions (baseline PO2 > 10 mm Hg). More interestingly, subline dependent behavior was found for initially hypoxic regions that correlated with rate of growth. The authors believe the FREDOM approach is essentially ripe for translation to the clinic. This approach could help to identify patients with hypoxic tumors and indicate the feasibility of manipulating tumor characteristics through adjuvant interventions to improve therapeutic response.

Original languageEnglish (US)
Pages (from-to)462-466
Number of pages5
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume24
Issue number5
DOIs
StatePublished - 2001

Fingerprint

Radiology
Oxygen
Echo-Planar Imaging
Neoplasms
Fluorocarbons
Oximetry
Prostate
Therapeutics
Growth

Keywords

  • Carbogen
  • Magnetic resonance imaging
  • Oximetry
  • Oxygen
  • Prognosis
  • Prostate tumor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Prognostic radiology : Quantitative assessment of tumor oxygen dynamics by MRI. / Zhao, Dawen; Constantinescu, Anca; Jiang, Lan; Hahn, Eric W.; Mason, Ralph P.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 24, No. 5, 2001, p. 462-466.

Research output: Contribution to journalArticle

Zhao, Dawen ; Constantinescu, Anca ; Jiang, Lan ; Hahn, Eric W. ; Mason, Ralph P. / Prognostic radiology : Quantitative assessment of tumor oxygen dynamics by MRI. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 2001 ; Vol. 24, No. 5. pp. 462-466.
@article{683ab6a5482147c781e4692e7a882494,
title = "Prognostic radiology: Quantitative assessment of tumor oxygen dynamics by MRI",
abstract = "It is generally recognized that tumor hypoxia has a strong influence over therapeutic outcome in the clinic. The authors have developed an oximetry approach using 19F echo planar magnetic resonance imaging-FREDOM (Fluorocarbon Relaxometry using Echoplanar imaging for Dynamic Oxygen Mapping), which reveals dynamic changes based on sequential maps of regional tumor PO2. Preclinical investigations focused on diverse sublines of the Dunning prostate R3327 tumor. As expected, intratumoral heterogeneity was considerable. However, large tumors (>3.5 cm3) were significantly less well oxygenated than smaller tumors (<2 cm3). Faster growing, less differentiated tumors were less well oxygenated than size-matched tumors of slower growing sublines. The greatest potential of this technique is the ability to follow the fate of individual tumor regions with respect to interventions. For each subline, there was a significant response to respiratory challenge with oxygen for initially well-oxygenated regions (baseline PO2 > 10 mm Hg). More interestingly, subline dependent behavior was found for initially hypoxic regions that correlated with rate of growth. The authors believe the FREDOM approach is essentially ripe for translation to the clinic. This approach could help to identify patients with hypoxic tumors and indicate the feasibility of manipulating tumor characteristics through adjuvant interventions to improve therapeutic response.",
keywords = "Carbogen, Magnetic resonance imaging, Oximetry, Oxygen, Prognosis, Prostate tumor",
author = "Dawen Zhao and Anca Constantinescu and Lan Jiang and Hahn, {Eric W.} and Mason, {Ralph P.}",
year = "2001",
doi = "10.1097/00000421-200110000-00010",
language = "English (US)",
volume = "24",
pages = "462--466",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Prognostic radiology

T2 - Quantitative assessment of tumor oxygen dynamics by MRI

AU - Zhao, Dawen

AU - Constantinescu, Anca

AU - Jiang, Lan

AU - Hahn, Eric W.

AU - Mason, Ralph P.

PY - 2001

Y1 - 2001

N2 - It is generally recognized that tumor hypoxia has a strong influence over therapeutic outcome in the clinic. The authors have developed an oximetry approach using 19F echo planar magnetic resonance imaging-FREDOM (Fluorocarbon Relaxometry using Echoplanar imaging for Dynamic Oxygen Mapping), which reveals dynamic changes based on sequential maps of regional tumor PO2. Preclinical investigations focused on diverse sublines of the Dunning prostate R3327 tumor. As expected, intratumoral heterogeneity was considerable. However, large tumors (>3.5 cm3) were significantly less well oxygenated than smaller tumors (<2 cm3). Faster growing, less differentiated tumors were less well oxygenated than size-matched tumors of slower growing sublines. The greatest potential of this technique is the ability to follow the fate of individual tumor regions with respect to interventions. For each subline, there was a significant response to respiratory challenge with oxygen for initially well-oxygenated regions (baseline PO2 > 10 mm Hg). More interestingly, subline dependent behavior was found for initially hypoxic regions that correlated with rate of growth. The authors believe the FREDOM approach is essentially ripe for translation to the clinic. This approach could help to identify patients with hypoxic tumors and indicate the feasibility of manipulating tumor characteristics through adjuvant interventions to improve therapeutic response.

AB - It is generally recognized that tumor hypoxia has a strong influence over therapeutic outcome in the clinic. The authors have developed an oximetry approach using 19F echo planar magnetic resonance imaging-FREDOM (Fluorocarbon Relaxometry using Echoplanar imaging for Dynamic Oxygen Mapping), which reveals dynamic changes based on sequential maps of regional tumor PO2. Preclinical investigations focused on diverse sublines of the Dunning prostate R3327 tumor. As expected, intratumoral heterogeneity was considerable. However, large tumors (>3.5 cm3) were significantly less well oxygenated than smaller tumors (<2 cm3). Faster growing, less differentiated tumors were less well oxygenated than size-matched tumors of slower growing sublines. The greatest potential of this technique is the ability to follow the fate of individual tumor regions with respect to interventions. For each subline, there was a significant response to respiratory challenge with oxygen for initially well-oxygenated regions (baseline PO2 > 10 mm Hg). More interestingly, subline dependent behavior was found for initially hypoxic regions that correlated with rate of growth. The authors believe the FREDOM approach is essentially ripe for translation to the clinic. This approach could help to identify patients with hypoxic tumors and indicate the feasibility of manipulating tumor characteristics through adjuvant interventions to improve therapeutic response.

KW - Carbogen

KW - Magnetic resonance imaging

KW - Oximetry

KW - Oxygen

KW - Prognosis

KW - Prostate tumor

UR - http://www.scopus.com/inward/record.url?scp=0034793879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034793879&partnerID=8YFLogxK

U2 - 10.1097/00000421-200110000-00010

DO - 10.1097/00000421-200110000-00010

M3 - Article

C2 - 11586097

AN - SCOPUS:0034793879

VL - 24

SP - 462

EP - 466

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 5

ER -